Phamacometabolomics study identifies circulating spermidine and tryptophan as potential biomarkers associated with the complete pathological response to trastuzumab-paclitaxel neoadjuvant therapy in HER-2 positive breast cancer

Oncotarget

Volumn 7, Issue 26, 2016, Pages 39809-39822

  Miolo, Gianmaria ^a   Muraro, Elena ^a   Caruso, Donatella ^b   Crivellari, Diana ^a   Ash, Anthony ^c   Scalone, Simona ^a   Lombardi, Davide ^a   Rizzolio, Flavio ^a   Giordano, Antonio ^d   Corona, Giuseppe ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c NORWICH RESEARCH PARK   (United Kingdom)

^d Temple University   (United States)

Author keywords

Breast; Cancer; Metabolomics; Pharmacometabolomics; Pharmacometabonomics

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; PACLITAXEL; SPERMIDINE; TRASTUZUMAB; TRYPTOPHAN; ANTINEOPLASTIC AGENT; ERBB2 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; AMINO ACID BLOOD LEVEL; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFECT; DRUG RESPONSE; HUMAN; LIQUID CHROMATOGRAPHY; METABOLITE; METABOLOMICS; SENSITIVITY AND SPECIFICITY; TANDEM MASS SPECTROMETRY; ADJUVANT CHEMOTHERAPY; BLOOD; BREAST TUMOR; FEMALE; GENETICS; LEAST SQUARE ANALYSIS; MIDDLE AGED; NEOADJUVANT THERAPY; PHARMACOGENETICS; RECEIVER OPERATING CHARACTERISTIC; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; LEAST-SQUARES ANALYSIS; MIDDLE AGED; NEOADJUVANT THERAPY; PACLITAXEL; PHARMACOGENETICS; RECEPTOR, ERBB-2; ROC CURVE; SPERMIDINE; TANDEM MASS SPECTROMETRY; TRASTUZUMAB; TREATMENT OUTCOME; TRYPTOPHAN; YOUNG ADULT;

EID: 84982920561     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.9489     Document Type: Article

References (46)

1. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001; 344:783-792.
2. Goldhirsch A, Gelber RD, Piccart-Gebhart MJ, de AE, Procter M, Suter TM, Jackisch C, Cameron D, Weber HA, Heinzmann D, Dal LL, McFadden E, Dowsett M, et al. 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial. Lancet. 2013; 382:1021-1028.
3. Smith I, Procter M, Gelber RD, Guillaume S, Feyereislova A, Dowsett M, Goldhirsch A, Untch M, Mariani G, Baselga J, Kaufmann M, Cameron D, Bell R, et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet. 2007; 369:29-36.
4. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D, Dowsett M, Barrios CH, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005; 353:1659-1672.
5. Gianni L, Eiermann W, Semiglazov V, Lluch A, Tjulandin S, Zambetti M, Moliterni A, Vazquez F, Byakhov MJ, Lichinitser M, Climent MA, Ciruelos E, Ojeda B, et al. Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet Oncol. 2014; 15:640-647.
6. von MG, Untch M, Blohmer JU, Costa SD, Eidtmann H, Fasching PA, Gerber B, Eiermann W, Hilfrich J, Huober J, Jackisch C, Kaufmann M, Konecny GE, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol. 2012; 30:1796-1804.
7. Kim MM, Allen P, Gonzalez-Angulo AM, Woodward WA, Meric-Bernstam F, Buzdar AU, Hunt KK, Kuerer HM, Litton JK, Hortobagyi GN, Buchholz TA, Mittendorf EA. Pathologic complete response to neoadjuvant chemotherapy with trastuzumab predicts for improved survival in women with HER2-overexpressing breast cancer. Ann Oncol. 2013; 24:1999-2004.
8. Buzdar AU, Valero V, Ibrahim NK, Francis D, Broglio KR, Theriault RL, Pusztai L, Green MC, Singletary SE, Hunt KK, Sahin AA, Esteva F, Symmans WF, et al. Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen. Clin Cancer Res. 2007; 13:228-233.
9. Houssami N, Macaskill P, von MG, Marinovich ML, Mamounas E. Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy. Eur J Cancer. 2012; 48:3342-3354.
10. Nahta R, Shabaya S, Ozbay T, Rowe DL. Personalizing HER2-targeted therapy in metastatic breast cancer beyond HER2 status: what we have learned from clinical specimens. Curr Pharmacogenomics Person Med. 2009; 7:263-274.
11. Krop IE, Burstein HJ. Trastuzumab. qui bono? J Natl Cancer Inst. 2013; 105:1772-1775.
12. Pogue-Geile KL, Kim C, Jeong JH, Tanaka N, Bandos H, Gavin PG, Fumagalli D, Goldstein LC, Sneige N, Burandt E, Taniyama Y, Bohn OL, Lee A, et al. Predicting degree of benefit from adjuvant trastuzumab in NSABP trial B-31. J Natl Cancer Inst. 2013; 105:1782-1788.
13. De P, Hasmann M, Leyland-Jones B. Molecular determinants of trastuzumab efficacy: What is their clinical relevance? Cancer Treat Rev. 2013; 39:925-934.
14. Arnould L, Gelly M, Penault-Llorca F, Benoit L, Bonnetain F, Migeon C, Cabaret V, Fermeaux V, Bertheau P, Garnier J, Jeannin JF, Coudert B. Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism? Br J Cancer. 2006; 94:259-267.
15. Fontanella C, Lederer B, Gade S, Vanoppen M, Blohmer JU, Costa SD, Denkert C, Eidtmann H, Gerber B, Hanusch C, Hilfrich J, Huober J, Schneeweiss A, et al. Impact of body mass index on neoadjuvant treatment outcome: a pooled analysis of eight prospective neoadjuvant breast cancer trials. Breast Cancer Res Treat. 2015; 150:127-139.
16. Clayton TA, Lindon JC, Cloarec O, Antti H, Charuel C, Hanton G, Provost JP, Le Net JL, Baker D, Walley RJ, Everett JR, Nicholson JK. Pharmaco-metabonomic phenotyping and personalized drug treatment. Nature. 2006; 440:1073-1077.
17. Clayton TA, Baker D, Lindon JC, Everett JR, Nicholson JK. Pharmacometabonomic identification of a significant host-microbiome metabolic interaction affecting human drug metabolism. Proc Natl Acad Sci USA. 2009; 106: 14728-14733.
18. Nicholson JK, Wilson ID, Lindon JC. Pharmacometabonomics as an effector for personalized medicine. Pharmacogenomics. 2011; 12:103-111.
19. Everett JR, Loo RL, Pullen FS. Pharmacometabonomics and personalized medicine. Ann Clin Biochem. 2013; 50:523-545.
20. Corona G, Rizzolio F, Giordano A, Toffoli G. Pharmacometabolomics: an emerging "omics" tool for the personalization of anticancer treatments and identification of new valuable therapeutic targets. J Cell Physiol. 2012; 227:2827-2831.
21. Kaddurah-Daouk R, Boyle SH, Matson W, Sharma S, Matson S, Zhu H, Bogdanov MB, Churchill E, Krishnan RR, Rush AJ, Pickering E, Delnomdedieu M. Pretreatment metabotype as a predictor of response to sertraline or placebo in depressed outpatients: a proof of concept. Transl Psychiatry. 2011; 1. pii: e26. doi: 10.1038/tp.2011.22.:e26.
22. Kaddurah-Daouk R, Weinshilboum RM. Pharmacometabolomics: implications for clinical pharmacology and systems pharmacology. Clin Pharmacol Ther. 2014; 95:154-167.
23. Krauss RM, Zhu H, Kaddurah-Daouk R. Pharmacometabolomics of statin response. Clin Pharmacol Ther. 2013; 94:562-565.
24. Phapale PB, Kim SD, Lee HW, Lim M, Kale DD, Kim YL, Cho JH, Hwang D, Yoon YR. An integrative approach for identifying a metabolic phenotype predictive of individualized pharmacokinetics of tacrolimus. Clin Pharmacol Ther. 2010; 87:426-436.
25. Zhu H, Bogdanov MB, Boyle SH, Matson W, Sharma S, Matson S, Churchill E, Fiehn O, Rush JA, Krishnan RR, Pickering E, Delnomdedieu M, Kaddurah-Daouk R. Pharmacometabolomics of response to sertraline and to placebo in major depressive disorder-possible role for methoxyindole pathway. PLoS One. 2013; 8:e68283.
26. Tenori L, Oakman C, Morris PG, Gralka E, Turner N, Cappadona S, Fornier M, Hudis C, Norton L, Luchinat C, Di LA. Serum metabolomic profiles evaluated after surgery may identify patients with oestrogen receptor negative early breast cancer at increased risk of disease recurrence. Results from a retrospective study. Mol Oncol. 2014; 10.
27. Wei S, Liu L, Zhang J, Bowers J, Gowda GA, Seeger H, Fehm T, Neubauer HJ, Vogel U, Clare SE, Raftery D. Metabolomics approach for predicting response to neoadjuvant chemotherapy for breast cancer. Mol Oncol. 2013; 7:297-307.
28. Ramani D, De Bandt JP, Cynober L. Aliphatic polyamines in physiology and diseases. Clin Nutr. 2014; 33:14-22.
29. Casero RA Jr, Wang Y, Stewart TM, Devereux W, Hacker A, Wang Y, Smith R, Woster PM. The role of polyamine catabolism in anti-tumour drug response. Biochem Soc Trans. 2003; 31:361-365.
30. Nowotarski SL, Woster PM, Casero RA Jr. Polyamines and cancer: implications for chemotherapy and chemoprevention. Expert Rev Mol Med. 2013;15:e3. doi: 10.1017/erm.2013.3.:e3.
31. Leveque J, Bansard JY, Watier E, Catros-Quemener V, Havouis R, Moulinoux JP, Grall JY, Seiler N. Polyamines in human breast cancer and its relations to classical prognostic features: clinical implications. Anticancer Res. 1999; 19:2275-2279.
32. Byun JA, Choi MH, Moon MH, Kong G, Chul CB. Serum polyamines in pre- and post-operative patients with breast cancer corrected by menopausal status. Cancer Lett. 2009; 273:300-304.
33. Tsutsui H, Mochizuki T, Inoue K, Toyama T, Yoshimoto N, Endo Y, Todoroki K, Min JZ, Toyo'oka T. High-throughput LC-MS/MS based simultaneous determination of polyamines including N-acetylated forms in human saliva and the diagnostic approach to breast cancer patients. Anal Chem. 2013; 85:11835-11842.
34. Mechulam A, Chernov KG, Mucher E, Hamon L, Curmi PA, Pastre D. Polyamine sharing between tubulin dimers favours microtubule nucleation and elongation via facilitated diffusion. PLoS Comput Biol. 2009; 5:e1000255.
35. Bender DA. Biochemistry of tryptophan in health and disease. Mol Aspects Med. 1983; 6:101-197.
36. Johnson TS, Munn DH. Host indoleamine 2, 3-dioxygenase: contribution to systemic acquired tumor tolerance. Immunol Invest 2012;41:765-797.
37. Mandi Y, Vecsei L. The kynurenine system and immunoregulation. J Neural Transm. 2012; 119:197-209.
38. Belladonna ML, Puccetti P, Orabona C, Fallarino F, Vacca C, Volpi C, Gizzi S, Pallotta MT, Fioretti MC, Grohmann U. Immunosuppression via tryptophan catabolism: the role of kynurenine pathway enzymes. Transplantation. 2007; 84:S17-S20.
39. Prendergast GC. Cancer. Why tumours eat tryptophan. Nature. 2011; 478:192-194.
40. Cascino A, Cangiano C, Ceci F, Franchi F, Mineo T, Mulieri M, Muscaritoli M, Rossi FF. Increased plasma free tryptophan levels in human cancer: a tumor related effect? Anticancer Res. 1991; 11:1313-1316.
41. Valabrega G, Montemurro F, Aglietta M. Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Ann Oncol. 2007; 18:977-984.
42. Kono K, Sato E, Naganuma H, Takahashi A, Mimura K, Nukui H, Fujii H. Trastuzumab (Herceptin) enhances class I-restricted antigen presentation recognized by HER-2/neu-specific T cytotoxic lymphocytes. Clin Cancer Res. 2004; 10:2538-2544.
43. Want EJ, Wilson ID, Gika H, Theodoridis G, Plumb RS, Shockcor J, Holmes E, Nicholson JK. Global metabolic profiling procedures for urine using UPLC-MS. Nat Protoc 2010; 5:1005-1018.
44. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. Journal of the Royal Statistical Society, Series B 1995; 57:289-300.
45. Xia J, Sinelnikov IV, Han B, Wishart DS. MetaboAnalyst 3.0-making metabolomics more meaningful. Nucleic Acids Res. 2015; 43:W251-W257.
46. Xia J, Broadhurst DI, Wilson M, Wishart DS: Translational biomarker discovery in clinical metabolomics: an introductory tutorial. Metabolomics. 2013; 9:280-299.